A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

Michael Dickinson, Anastasios Karadimitris, Aristeidis Chaidos et al.|Blood|2018

Cited by 15